On the occasion of World Immunization Week, the British Embassy in Korea, the British Chamber of Commerce in Korea, and GSK ...

A new version has now started testing, while GSK has also focused on providing its adjuvant technology to other developers like South Korea's SK bio. In the midst of that, Hanon left GSK in April ...

Cha Seung-won was selected as a model for the Respiratory Synthetic Virus (RSV) vaccine 'AlexB'. GSK Korea announced that it ...

Specific diseases covered by the pact were not disclosed. The deal kicks off with GSK paying South Korea-based ABL £38.5 million (about $49.1 million) up front. The drug delivery approach of ABL ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

Korea GSK announced on the 10th that it has selected actress Lee Jung-hyun as the official model for its new advertising campaign for the only domestic meningococcal B vaccine 'Bexsero ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ... payments to get access to Seongnam, South Korea-based ABL's Grabody-B platform technology ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL ... announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL ...